Table 5.

Compared proportions of MTD recommendation and accuracy measure for the optimal design and CRM-L after 10,000 simulated trials. The true MTD is indicated in bold type. The target toxicity rate is 20% and the fixed sample size for each trial is 30 patients. First stage cohort size is 1.

Dose	1	2	3	4	5	6	7	8	A(n)
Scenario 13	0.09	0.20	0.26	0.44	0.58	0.74	0.83	0.90
CRM-L (A)	0.19	0.49	0.28	0.04	0.00	0.00	0.00	0.00	0.858
CRM-L (B)	0.21	0.46	0.29	0.04	0.00	0.00	0.00	0.00	0.848
Optimal	0.14	0.48	0.35	0.03	0.00	0.00	0.00	0.00	0.868
Scenario 14	0.05	0.10	0.20	0.30	0.45	0.58	0.70	0.81
CRM-L (A)	0.02	0.23	0.49	0.24	0.02	0.00	0.00	0.00	0.788
CRM-L (B)	0.02	0.23	0.48	0.24	0.02	0.00	0.00	0.00	0.784
Optimal	0.01	0.15	0.55	0.28	0.01	0.00	0.00	0.00	0.818
Scenario 15	0.02	0.05	0.11	0.20	0.33	0.48	0.60	0.72
CRM-L (A)	0.00	0.03	0.25	0.51	0.20	0.01	0.00	0.00	0.744
CRM-L (B)	0.00	0.03	0.25	0.51	0.20	0.01	0.00	0.00	0.742
Optimal	0.00	0.01	0.19	0.58	0.22	0.01	0.00	0.00	0.778
Scenario 16	0.01	0.04	0.07	0.10	0.18	0.31	0.50	0.64
CRM-L (A)	0.00	0.00	0.04	0.20	0.49	0.26	0.02	0.00	0.627
CRM-L (B)	0.00	0.00	0.03	0.20	0.50	0.24	0.02	0.0	0.625
Optimal	0.00	0.00	0.02	0.11	0.55	0.31	0.01	0.00	0.664
Scenario 17	0.01	0.02	0.04	0.06	0.08	0.13	0.20	0.36
CRM-L (A)	0.00	0.00	0.01	0.03	0.09	0.26	0.46	0.15	0.546
CRM-L (B)	0.00	0.00	0.00	0.02	0.09	0.28	0.44	0.17	0.526
Optimal	0.00	0.00	0.00	0.01	0.04	0.22	0.58	0.17	0.635
Scenario 18	0.01	0.03	0.05	0.07	0.09	0.11	0.14	0.20
CRM-L (A)	0.00	0.00	0.01	0.04	0.08	0.13	0.25	0.48	0.619
CRM-L (B)	0.00	0.00	0.01	0.03	0.07	0.12	0.23	0.53	0.654
Optimal	0.00	0.00	0.00	0.01	0.03	0.08	0.21	0.66	0.769

Avg. A(n): CRM-L (A) = 0.697; CRM-L(B) = 0.696; Optimal = 0.755